Esperion Therapeutics (ESPR) Preferred Stock Liabilities (2012 - 2013)
Esperion Therapeutics (ESPR) reported Preferred Stock Liabilities of $65.2 million for Q2 2013, up 172.07% quarter-over-quarter from $24.0 million in Q4 2012.
Esperion Therapeutics (ESPR) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Esperion Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $65.2 million in Q2 2013.
- For the quarter ending Q2 2013, Preferred Stock Liabilities changed N/A year-over-year to $65.2 million; the trailing twelve-month figure through Jun 2013 stood at $65.2 million (changed N/A YoY), and the FY2012 full-year result was $24.0 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities for Q2 2013 stood at $65.2 million, up from $24.0 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $65.2 million in Q2 2013, with the low at $24.0 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Esperion Therapeutics | 49.69 Mn | -118.16 Mn | 45.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 65.23 Mn |
| Dec 31, 2012 | 23.98 Mn |